Sobetirome
Sobetirome is a thyromimetic drug that binds to the thyroid [hormone receptor] TRβ1 preferentially compared to TRα1. It has been investigated for the treatment of dyslipidemia, obesity, Pitt–Hopkins syndrome, cholestatic [liver disease], multiple sclerosis, bleomycin-induced lung fibrosis, and COVID-19 caused ARDS. It was designated as an orphan drug by the FDA for the treatment of X-linked adrenoleukodystrophy.